Paper28242552
Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
Monjas L and 9 others. Eur J Med Chem, 2017. Cited by 19 papers, by iCite.
Cite this record
ConductScience Library. Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia. Papers, record 28242552. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28242552
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Alzheimer Disease | Major topic |
| Brain Ischemia | Major topic |
| Glutamates | Major topic |
| Indans | Major topic |
| Piperidines | Major topic |
| Animals | |
| Calcium Channel Blockers | |
| Cholinesterase Inhibitors | |
| Donepezil | |
| Hippocampus | |
| Humans | |
| Neuroprotective Agents | |
| Rats | |
| Solid-Phase Synthesis Techniques |
Source PubMed
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39760808 | From Genes to Metabolites: HSP90B1's Role in Alzheimer's Disease and Potential for Therapeutic Intervention. | Neuromolecular Med | 2025 | https://conductscience.org/library/papers/39760808 | PubMed |
| 36978399 | Conjugation as a Tool in Therapeutics: Role of Amino Acids/Peptides-Bioactive (Including Heterocycles) Hybrid Molecules in Treating Infectious Diseases. | Antibiotics (Basel) | 2023 | https://conductscience.org/library/papers/36978399 | PubMed |
| 35498922 | The recent development of donepezil structure-based hybrids as potential multifunctional anti-Alzheimer's agents: highlights from 2010 to 2020. | RSC Adv | 2021 | https://conductscience.org/library/papers/35498922 | PubMed |
| 35347587 | Molecular Insights into Therapeutic Potentials of Hybrid Compounds Targeting Alzheimer's Disease. | Mol Neurobiol | 2022 | https://conductscience.org/library/papers/35347587 | PubMed |
| 31852270 | New flavonoid - N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for Alzheimer´s disease endowed with neurogenic properties. | J Enzyme Inhib Med Chem | 2019 | https://conductscience.org/library/papers/31852270 | PubMed |
| 31391892 | The synthesis and biological evaluation of novel gardenamide A derivatives as multifunctional neuroprotective agents. | Medchemcomm | 2019 | https://conductscience.org/library/papers/31391892 | PubMed |
| 29529892 | Profiling donepezil template into multipotent hybrids with antioxidant properties. | J Enzyme Inhib Med Chem | 2018 | https://conductscience.org/library/papers/29529892 | PubMed |
| 28966636 | Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer's disease therapy. | Neural Regen Res | 2017 | https://conductscience.org/library/papers/28966636 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28242552
GET https://conductscience.org/api/papers/v1/28242552/authors